Self-renewal as a therapeutic target in human colorectal cancer

Nature Medicine

Volumn 20, Issue 1, 2014, Pages 29-36

  Kreso, Antonija ^a,b   Van Galen, Peter ^a   Pedley, Nicholas M ^a,b   Lima Fernandes, Evelyne ^c   Frelin, Catherine ^a,b   Davis, Thomas ^d   Cao, Liangxian ^d   Baiazitov, Ramil ^d   Du, Wu ^d   Sydorenko, Nadiya ^d   Moon, Young Choon ^d   Gibson, Lianne ^a,b   Wang, Yadong ^a,b   Leung, Cherry ^a,b   Iscove, Norman N ^a,b   Arrowsmith, Cheryl H ^a,b,c   Szentgyorgyi, Eva ^e   Gallinger, Steven ^e,f   Dick, John E ^a,b   O'Brien, Catherine A ^a,b,e  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Structural Genomics Consortium   (Canada)

^d PTC THERAPEUTICS   (United States)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BMI1 PROTEIN; PTC 209; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; COLON CARCINOGENESIS; COLORECTAL CANCER; DOWN REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BLOTTING, WESTERN; BROMODEOXYURIDINE; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FLOW CYTOMETRY; GENETIC VECTORS; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; LUCIFERASES; MICE, INBRED NOD; MICE, SCID; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; POLYCOMB REPRESSIVE COMPLEX 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; THIAZOLES;

EID: 84891852738     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3418     Document Type: Article

References (42)

1. Dick, J.E. Stem cell concepts renew cancer research. Blood 112, 4793-4807 (2008).
2. O'Brien, C.A., Pollett, A., Gallinger, S. &Dick, J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-110 (2007).
3. Ricci-Vitiani, L. et al. Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115 (2007).
4. Dalerba, P. et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 104, 10158-10163 (2007).
5. Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006).
6. Li, X. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100, 672-679 (2008).
7. Tehranchi, R. et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N. Engl. J. Med. 363, 1025-1037 (2010).
8. Majeti, R. et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286-299 (2009).
9. Todaro, M. et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1, 389-402 (2007).
10. Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543-548 (2013).
11. Singh, S.K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
12. Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J. &Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 3983-3988 (2003).
13. O'Brien, C.A. et al. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell 21, 777-792 (2012).
14. Park, I.K. et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302-305 (2003).
15. Lessard, J. &Sauvageau, G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423, 255-260 (2003).
16. Molofsky, A.V. et al. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425, 962-967 (2003).
17. Sparmann, A. &van Lohuizen, M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6, 846-856 (2006).
18. Sauvageau, M. &Sauvageau, G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7, 299-313 (2010).
19. Sangiorgi, E. &Capecchi, M.R. Bmi1 is expressed in vivo in intestinal stem cells. Nat. Genet. 40, 915-920 (2008).
20. Tian, H. et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 478, 255-259 (2011).
21. Bruggeman, S.W. et al. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 12, 328-341 (2007).
22. Leung, C. et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428, 337-341 (2004).
23. Shimono, Y. et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 138, 592-603 (2009).
24. Lukacs, R.U., Memarzadeh, S., Wu, H. &Witte, O.N. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 7, 682-693 (2010).
25. Dovey, J.S., Zacharek, S.J., Kim, C.F. &Lees, J.A. Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc. Natl. Acad. Sci. USA 105, 11857-11862 (2008).
26. Chiba, T. et al. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res. 68, 7742-7749 (2008).
27. Abdouh, M. et al. BMI1 sustains human glioblastoma multiforme stem cell renewal. J. Neurosci. 29, 8884-8896 (2009).
28. Kim, J.H. et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 203, 217-224 (2004).
29. Li, D.W. et al. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J. Cancer Res. Clin. Oncol. 136, 997-1006 (2010).
30. Du, J., Li, Y., Li, J. &Zheng, J. Polycomb group protein Bmi1 expression in colon cancers predicts the survival. Med. Oncol. 27, 1273-1276 (2010).
31. Tateishi, K. et al. Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract. Clin. Cancer Res. 12, 6960-6966 (2006).
32. Vermeulen, L. et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468-476 (2010).
33. Dylla, S.J. et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE 3, e2428 (2008).
34. Wang, J.C. Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm. Cell Stem Cell 1, 497-501 (2007).
35. Kvinlaug, B.T. &Huntly, B.J. Targeting cancer stem cells. Expert Opin. Ther. Targets 11, 915-927 (2007).
36. Trumpp, A. &Wiestler, O.D. Mechanisms of disease: cancer stem cells-targeting the evil twin. Nat. Clin. Pract. Oncol. 5, 337-347 (2008).
37. Liu, S. &Wicha, M.S. Targeting breast cancer stem cells. J. Clin. Oncol. 28, 4006-4012 (2010).
38. Diehn, M., Cho, R.W. &Clarke, M.F. Therapeutic implications of the cancer stem cell hypothesis. Semin. Radiat. Oncol. 19, 78-86 (2009).
39. Kreso, A. &O'Brien, C.A. Colon cancer stem cells. Curr. Protoc. Stem Cell Biol. 7, 3.1 (2008).
40. Hu, Y. &Smyth, G.K. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347, 70-78 (2009).
41. Amendola, M., Venneri, M.A., Biffi, A., Vigna, E. &Naldini, L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat. Biotechnol. 23, 108-116 (2005).
42. Voorhoeve, P.M. &Agami, R. The tumor-suppressive functions of the human INK4A locus. Cancer Cell 4, 311-319 (2003).